Reductions to the price of three multiple sclerosis (MS) drugs mean National Institute for Health and Care Excellence (NICE) is now able to recommend them for routine NHS funding. NICE has published draft guidance recommending interferon beta-1b (Extavia, Novartis), glatiramer acetate (Copaxone, Teva UK Ltd), and interferon beta-1a (Avonex, Biogen Idec Ltd, and Rebif, Merck…